Syndax Pharmaceuticals, Inc. (SNDX)

Syndax Pharmaceuticals, Inc. (SNDX) Healthcare & Pipeline Overview

Syndax Pharmaceuticals, Inc. is a clinical-stage biotechnology firm specializing in innovative cancer therapies, including SNDX-5613 for acute myeloid leukemia and axatilimab for chronic graft versus host disease. The company leverages strategic collaborations to advance its pipeline, positioning it within the competitive oncology drug development landscape.

What Is the Investment Thesis for SNDX?

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company with a market capitalization of $1.96B, focused on developing therapies for cancer and chronic graft versus host disease. The investment thesis centers on the potential of its lead product candidates, SNDX-5613 and axatilimab, to address significant unmet medical needs. SNDX-5613, currently in Phase 1/2 trials for MLLr and NPM1c AML, targets a specific oncogenic pathway, offering a precision medicine approach. Positive clinical data readouts from these trials would serve as a critical catalyst, potentially de-risking the asset and increasing its perceived market value. Axatilimab, a monoclonal antibody for cGVHD, also represents a substantial market opportunity, with ongoing clinical development providing future milestones. Despite a negative profit margin of -112.0%, which is typical for a clinical-stage biotechnology company, Syndax exhibits a high gross margin of 98.0%, indicating strong pricing potential if products reach commercialization. The company's beta of 0.41 suggests lower volatility compared to the broader market, which might appeal to certain investors. Future value drivers include successful progression of clinical trials, potential regulatory approvals, and the establishment of commercial partnerships. The company's collaborative agreements with entities like the National Cancer Institute and Kyowa Hakko Kirin Co., Ltd., further validate its scientific approach and provide potential avenues for resource leverage and market access.

Based on FMP financials and quantitative analysis

SNDX Key Highlights

• Market capitalization stands at $1.75 billion, reflecting its valuation as a clinical-stage biotechnology company.
• Gross margin of 98.0% indicates strong potential profitability if lead candidates achieve commercialization.
• Operating with a profit margin of -112.0%, typical for a company in the research and development phase with no commercialized products.
• Beta of 0.41 suggests the stock has historically exhibited lower volatility compared to the overall market.
• Focused development on two lead product candidates, SNDX-5613 for AML and axatilimab for cGVHD, both in clinical trials.

Who Are SNDX's Competitors?

SNDX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SNDX's Key Strengths?

• Focused pipeline with two lead candidates addressing high unmet medical needs (AML, cGVHD).
• High gross margin (98.0%) indicates strong potential profitability post-commercialization.
• Strategic collaborations with reputable institutions like the National Cancer Institute and Kyowa Hakko Kirin.
• Precision medicine approach for SNDX-5613 targets specific genetic mutations.

What Are SNDX's Weaknesses?

• Clinical-stage company with no commercialized products, leading to negative profit margin (-112.0%).
• High dependence on the success of a limited number of pipeline candidates.
• Significant capital requirements for ongoing R&D and clinical trials.
• Reliance on external partnerships for certain aspects of development and potential commercialization.

What Could Drive SNDX Stock Higher?

• Data readouts from the ongoing Phase 1/2 clinical trial for SNDX-5613 in MLLr and NPM1c AML.
• Regulatory submissions and potential approval decisions for axatilimab in chronic graft versus host disease (cGVHD).
• Progression of axatilimab (SNDX-6352) through later-stage clinical trials for cGVHD.
• Further development and potential expansion of Entinostat's clinical program.
• Announcement of new strategic partnerships or licensing agreements to support pipeline advancement.

What Are the Key Risks for SNDX?

• Financial-distress signal — its Altman Z-Score of -1.60 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unexpected adverse events for lead candidates SNDX-5613 and axatilimab.
• Regulatory delays or failure to obtain marketing approval for its drug candidates from health authorities.
• Significant capital requirements and the need for future financing to fund extensive research and development activities.
• Intense competition from other biopharmaceutical companies developing similar or superior therapies.
• Intellectual property challenges or the inability to maintain patent protection for its pipeline assets.

What Are the Growth Opportunities for SNDX?

• Growth opportunity 1: Successful Clinical Development and Commercialization of SNDX-5613. SNDX-5613, currently in Phase 1/2 clinical trials, targets MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). The global AML market is projected to reach significant values, driven by the need for more effective treatments for these aggressive forms of leukemia. Successful progression through later-stage clinical trials, followed by regulatory approval, would unlock a substantial market opportunity. The precision medicine approach of SNDX-5613, targeting specific genetic mutations, positions it to potentially capture a niche but high-value patient population, offering a differentiated therapeutic option within the next 3-5 years.
• Growth opportunity 2: Regulatory Approval and Market Penetration of Axatilimab (SNDX-6352). Axatilimab, a monoclonal antibody blocking the CSF-1 receptor, is being developed for chronic graft versus host disease (cGVHD). cGVHD represents a serious complication post-transplant with limited treatment options, indicating a high unmet medical need. The global cGVHD market is expected to grow, driven by an increasing number of allogeneic stem cell transplants. Achieving regulatory approval for axatilimab would allow Syndax to enter this specialized market, potentially establishing a new standard of care. The timeline for this opportunity is contingent on ongoing clinical trial success and regulatory review, likely within the next 2-4 years.
• Growth opportunity 3: Expansion of Entinostat's Therapeutic Indications. While not a lead candidate, Entinostat is an epigenetic therapy in Syndax's pipeline. Expanding its development into additional oncology indications beyond its current scope could significantly broaden its market potential. Epigenetic modulators are an area of active research in cancer therapy, and demonstrating efficacy in new patient populations or in combination with other agents could unlock new revenue streams. This opportunity would involve further clinical trials and regulatory submissions, with a potential timeline extending beyond 5 years, depending on the specific indications pursued.
• Growth opportunity 4: Strategic Partnerships and Licensing Agreements. Syndax has a history of collaborative agreements, including with the National Cancer Institute and Kyowa Hakko Kirin Co., Ltd. For a clinical-stage company, forming additional strategic partnerships for its pipeline assets, particularly for late-stage development or commercialization, could provide crucial funding, reduce development risk, and expand geographic reach. Such collaborations could involve out-licensing rights for specific regions or co-development agreements, potentially accelerating market entry and maximizing the value of its intellectual property within the next 1-3 years.
• Growth opportunity 5: Pipeline Expansion through In-licensing or Acquisitions. To sustain long-term growth and diversify risk associated with a clinical-stage pipeline, Syndax could pursue in-licensing promising early-stage assets or acquiring smaller biotechnology companies with complementary technologies or therapeutic candidates. This strategy would broaden its therapeutic portfolio, potentially targeting new disease areas or enhancing existing programs. Such inorganic growth opportunities would depend on available capital and strategic fit, with potential impacts on the company's trajectory over a 3-7 year timeframe.

What Opportunities Does SNDX Have?

• Potential for regulatory approval and commercialization of SNDX-5613 and axatilimab.
• Expansion of therapeutic indications for existing pipeline assets like Entinostat.
• Formation of new strategic partnerships to accelerate development and market access.
• In-licensing or acquisition of complementary assets to diversify the pipeline.

What Threats Does SNDX Face?

• Clinical trial failures or delays for lead product candidates.
• Intense competition from larger pharmaceutical companies and other biotechs.
• Regulatory hurdles and potential challenges in obtaining market approval.
• Patent expirations or challenges to intellectual property.
• Market acceptance and reimbursement challenges for new therapies.

What Are SNDX's Competitive Advantages?

• Proprietary clinical-stage drug candidates, particularly SNDX-5613 and axatilimab, targeting specific biological pathways.
• Intellectual property protection (patents) for its drug compounds and methods of use.
• Specialized expertise in oncology and immunology drug development.
• Strategic collaborations with research institutions and pharmaceutical partners.

What Does SNDX Do?

Incorporated in 2005, Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of novel therapies for cancer treatment. Headquartered in Waltham, Massachusetts, the company focuses on addressing significant unmet medical needs in oncology and severe immune disorders. Syndax's strategic evolution has centered on building a robust pipeline of product candidates that target distinct mechanisms of action, aiming to provide differentiated treatment options for patients. The company's lead product candidate, SNDX-5613, is currently in a phase 1/2 clinical trial. This investigational therapy targets the binding interaction of Menin with the mixed lineage leukemia 1 protein, a critical pathway in specific hematologic malignancies. SNDX-5613 is being developed for the treatment of MLL-rearranged (MLLr) acute myeloid leukemia (AML) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML), both aggressive forms of leukemia with limited effective treatment options. The development of SNDX-5613 represents a key focus for Syndax in precision oncology. Another significant product candidate in Syndax's pipeline is SNDX-6352, also known as axatilimab. This is a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor. Axatilimab is being investigated for the treatment of patients with chronic graft versus host disease (cGVHD), a serious and often life-threatening complication that can occur after an allogeneic stem cell transplant. The company's efforts in cGVHD underscore its commitment to addressing immune-mediated conditions with high unmet needs. Beyond its lead candidates, Syndax is also developing Entinostat. The company actively engages in collaborative research and development efforts, including agreements with the National Cancer Institute and a clinical trial agreement with the Eastern Cooperative Oncology Group. Furthermore, Syndax holds a license agreement with Kyowa Hakko Kirin Co., Ltd., demonstrating its strategy of leveraging external partnerships to expand its therapeutic reach and accelerate drug development. With 270 employees, Syndax maintains a focused approach on advancing its clinical pipeline to bring innovative treatments to patients.

What Products and Services Does SNDX Offer?

• Develops clinical-stage therapies for cancer treatment.
• Advances SNDX-5613 for MLL-rearranged (MLLr) and NPM1c acute myeloid leukemia (AML).
• Develops SNDX-6352 (axatilimab) for chronic graft versus host disease (cGVHD).
• Researches and develops Entinostat, an epigenetic therapy.
• Engages in collaborative research with institutions like the National Cancer Institute.
• Holds a license agreement with Kyowa Hakko Kirin Co., Ltd.
• Focuses on precision medicine approaches for hematologic malignancies.
• Aims to address unmet medical needs in oncology and severe immune disorders.

How Does SNDX Make Money?

• Primarily generates value through the research, development, and clinical advancement of novel drug candidates.
• Future revenue generation is contingent upon successful regulatory approval and commercialization of its pipeline products.
• May derive revenue from licensing agreements and collaborations, potentially including upfront payments, milestone payments, and royalties.
• Operates with a high R&D expenditure typical of a clinical-stage biopharmaceutical company.

What Industry Does SNDX Operate In?

Syndax Pharmaceuticals operates within the highly dynamic and competitive biotechnology industry, specifically focusing on oncology and immunology, which are areas characterized by significant unmet medical needs and high research and development investment. The broader healthcare sector is experiencing robust growth driven by an aging global population, increasing prevalence of chronic diseases, and advancements in scientific understanding. Within oncology, there is a strong trend towards precision medicine and targeted therapies, aligning with Syndax's development of SNDX-5613 for specific AML mutations. The market for novel cancer treatments and therapies for rare immune disorders like cGVHD is substantial, with a constant demand for more effective and safer options. Competition is intense, encompassing large pharmaceutical companies with extensive resources and numerous smaller biopharmaceutical firms vying for market share with innovative pipelines. Syndax's strategy involves targeting specific, high-need indications where its candidates could offer differentiated clinical benefits.

Who Are SNDX's Key Customers?

• Ultimately, patients suffering from MLL-rearranged and NPM1c acute myeloid leukemia.
• Patients diagnosed with chronic graft versus host disease (cGVHD).
• Oncologists and hematologists who prescribe cancer and immune disorder treatments.
• Healthcare systems and payers seeking innovative therapies for complex diseases.

Net buyingInsider Activity

Over the past six months, Syndax Pharmaceuticals, Inc. insiders filed 27 SEC Form 4 transactions — 8 sales and 19 purchases. On net that is roughly 1.2M shares acquired (about $13.6M) — insiders putting money in tends to read as conviction.

SNDX Valuation & Market Position

With a $1.96B market cap, Syndax Pharmaceuticals, Inc. sits in the small-cap segment of the market. Relative to its peer group, SNDX's quantitative score of 9/100 is below the peer average of 75/100.

Key Financial Metrics

Return on assets is -51.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -15.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.4%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Syndax Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.60 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Syndax Pharmaceuticals, Inc. revenue of about $344.5M for fiscal 2026, with EPS near $-1.78. The estimate reflects 9 contributing analysts.

Company Profile

Syndax Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Michael A. Metzger. SNDX has traded publicly since 2016.

SNDX Financials

SNDX Latest News

SNDX Analyst Consensus

SNDX MoonshotScore

Syndax Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources